SCHEMBL14725975

SCHEMBL14725975

COc1cccc(-c2nc(Cl)c3cncn3n2)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 3/20 0.47
NR1H3 Q13133 3/20 0.47
SMN1; SMN2 Q16637 6/20 0.46
MAPT P10636 6/20 0.46
CYP1A2 P05177 4/20 0.46
CYP3A4 P08684 4/20 0.46
TP53 P04637 3/20 0.46
CYP2D6 P10635 3/20 0.46
CYP2C19 P33261 3/20 0.46
LMNA P02545 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
MAPK1 P28482 1/20 0.46
DYRK1A Q13627 1/20 0.46
CLK4 Q9HAZ1 1/20 0.46
BRD9 Q9H8M2 1/20 0.46
DHPS P49366 1/20 0.45
NPC1 O15118 4/20 0.44
RAB9A P51151 4/20 0.44
CYP2C9 P11712 3/20 0.43
SRC P12931 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18599844 0.86 NR1H2 (0.48) NR1H2NR1H3SMN1; SMN2MAPTCYP1A2
SCHEMBL14725978 0.85 NR1H2 (0.47) NR1H2NR1H3SMN1; SMN2MAPTCYP1A2
SCHEMBL14725977 0.77 PIK3CA (0.52) CYP1A2CYP3A4TP53CYP2D6CYP2C19
SCHEMBL18599848 0.76 CRHR1 (0.42) NR1H2NR1H3SMN1; SMN2MAPTCYP1A2
SCHEMBL14725992 0.76 ALDH1A3 (0.54) SMN1; SMN2MAPTTP53LMNABRD9
SCHEMBL10367722 0.72 DHPS (0.62) NR1H2NR1H3SMN1; SMN2MAPTCYP1A2
SCHEMBL1592678 0.70 CLK4 (0.61) NR1H2NR1H3SMN1; SMN2MAPTCYP1A2
SCHEMBL4126244 0.70 CLK4 (0.61) NR1H2NR1H3SMN1; SMN2MAPTCYP1A2
SCHEMBL18343222 0.69 CYP1A2 (0.55) SMN1; SMN2MAPTCYP1A2CYP3A4TP53
SCHEMBL27694078 0.68 CYP1A2 (0.72) SMN1; SMN2MAPTCYP1A2CYP3A4TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2526102-B1 Inhibitors of PI3 kinase FUNDACIÓN CENTRO NAC DE INVESTIG ONCOLÓGICAS CARLOS III (ES) 2017-03-08 EP disclosed
US-9073927-B2 Inhibitors of PI3 kinase FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III (ES) 2015-07-07 US disclosed
US-9073927-B2 Inhibitors of PI3 kinase FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III (ES) 2015-07-07 US disclosed
US-20130053371-A1 INHIBITORS OF PI3 KINASE CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) 2013-02-28 US disclosed
US-20130053371-A1 INHIBITORS OF PI3 KINASE CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) 2013-02-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130053371-A1 INHIBITORS OF PI3 KINASE PIK3CA, MTOR, PIK3C2A NR1H2 2181/4885NR1H3 1685/4885SMN1; SMN2 3009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.